This irreversible pan-HER TKI was evaluated in a phase I clinical trial with a phase II expansion arm, where Chinese patients with HER2-positive advanced breast cancer pre-treated with at least two lines of therapy were randomised to receive pyrotinib/capecitabine or lapatinib/capecitabine [66,67]. The gene discussed is ERBB2; the disease is breast carcinoma.